Search results for "INTENTION"

showing 10 items of 453 documents

Reasoned and implicit processes in heavy episodic drinking: An integrated dual-process model.

2019

Objectives University students commonly engage in heavy episodic drinking (HED), which contributes to injury risk, deleterious educational outcomes, and economic costs. Identification of the determinants of this risky behaviour may provide formative evidence on which to base effective interventions to curb HED in this population. Drawing from theories of social cognition and dual-process models, this study tested key hypotheses relating to reasoned and implicit pathways to action for HED in a sample of Australian university students who drink alcohol. Design A two-wave correlational design was adopted. Methods Students (N = 204) completed self-reported constructs from social cognition theor…

AdultMalemedia_common.quotation_subjectPopulationIdentity (social science)Poison controlIntentionDevelopmental psychologyBinge Drinking03 medical and health sciencesHabitsYoung Adult0302 clinical medicineRisk-TakingSocial cognitionHumans030212 general & internal medicineeducationSocial BehaviorStudentsApplied Psychologymedia_commoneducation.field_of_study030505 public healthTheory of planned behaviorAustraliaHuman factors and ergonomicsGeneral MedicineAlcohol Drinking in CollegeFemaleHabitSelf Report0305 other medical sciencePsychologyAttitude to HealthSocial cognitive theoryBritish journal of health psychologyReferences
researchProduct

Teprotumumab for Thyroid-Associated Ophthalmopathy

2017

Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns. Inhibition of the insulin-like growth factor I receptor (IGF-IR) is a new therapeutic strategy to attenuate the underlying autoimmune pathogenesis of ophthalmopathy.We conducted a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients with active, moderate-to-severe ophthalmopathy. A total of 88 patients were randomly assigned to r…

AdultMalemedicine.medical_specialty030209 endocrinology & metabolismDiseaseAdult; Aged; Antibodies Monoclonal; Diabetes Complications; Double-Blind Method; Exophthalmos; Female; Graves Ophthalmopathy; Humans; Hyperglycemia; Immunologic Factors; Insulin-Like Growth Factor I; Intention to Treat Analysis; Logistic Models; Male; Middle Aged; Quality of LifeAntibodies Monoclonal HumanizedPlaceboAntibodiesReceptor IGF Type 1law.inventionDiabetes ComplicationsGraves' ophthalmopathy03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicineMonoclonalmedicineClinical endpointExophthalmosHumansImmunologic FactorsInsulin-Like Growth Factor IAgedIntention-to-treat analysisTeprotumumabbusiness.industryAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseIntention to Treat AnalysisGraves OphthalmopathyLogistic ModelsHyperglycemiaMonoclonalImmunologyQuality of Life030221 ophthalmology & optometryFemalebusinessmedicine.drugNew England Journal of Medicine
researchProduct

Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: 5-year follow-up.

2011

Objective To study the long-term outcome of arthroscopy in patients with chronic patellofemoral pain syndrome (PFPS), the authors conducted a randomised controlled trial. The authors also investigated factors predicting the outcome in patients with PFPS. Methods Fifty-six patients with PFPS were randomised into two groups: an arthroscopy group (N=28), treated with knee arthroscopy and an 8-week home exercise programme, and a control group (N=28), treated with a similar 8-week home exercise programme only. The primary outcome was the Kujala score on pain and function at 5-year. Secondary outcomes were visual analogue scales (VASs) to assess activity-related symptoms. Results According to the…

AdultMalemedicine.medical_specialty5 year follow upPhysical Therapy Sports Therapy and Rehabilitationlaw.inventionArthroscopyYoung AdultRandomized controlled triallawmedicineHumansOrthopedics and Sports MedicineIn patientYoung adultta315Knee arthroscopyIntention-to-treat analysismedicine.diagnostic_testbusiness.industryArthroscopyGeneral Medicinemedicine.diseaseCombined Modality TherapyExercise TherapyIntention to Treat AnalysisTreatment OutcomePatellofemoral Pain SyndromeChronic DiseasePhysical therapyFemalebusinessPatellofemoral pain syndromeFollow-Up StudiesBritish journal of sports medicine
researchProduct

Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy

2014

Abstract Background Infliximab is effective as rescue therapy in severe corticosteroid-refractory ulcerative colitis. The optimal dose regimen and the long term benefits are not well defined. The aim of the present study was to evaluate short- and long-term colectomy rate in a cohort of patients with severe corticosteroid-refractory ulcerative colitis who received a three-dose infliximab induction regimen. Methods One hundred and thirteen patients admitted to 11 Italian IBD referral centres and treated with infliximab according to an intention to treat three-dose regimen were included. The co-primary endpoints were 3- and 12-month colectomy rate. The secondary end-points were the overall co…

AdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIAmedicine.medical_treatmentUlcerative colitis;GastroenterologyDrug Administration ScheduleYoung AdultAdrenal Cortex HormonesInternal medicineHumansMedicineTreatment FailureAdverse effectColectomyInfliximab;AgedColectomyIntention-to-treat analysisbusiness.industryAnti-Inflammatory Agents Non-SteroidalGastroenterologyAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseUlcerative colitisInfliximabInfliximabRegimenTreatment OutcomeUlcerative colitisRelative riskCohortColitis UlcerativeFemalebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Decline in motor prediction in elderly subjects: right versus left arm differences in mentally simulated motor actions.

2008

This study investigates the effects of age upon the temporal features of executed and imagined movements performed with the dominant (D; right) and nondominant (ND; left) arms. Thirty right-handed subjects were divided into two groups: (i) the young group (n=15; mean age: 22.5+/-2.5 years) and (ii) the elderly group (n=15; mean age: 70.2+/-2.2 years). The motor task, involving arm pointing movements among four pairs of targets (.5cm, 1cm, 1.5cm and 2cm), imposed strong spatiotemporal constraints. During overt performance, young and elderly subjects modulated movement duration according to the size of targets, despite the fact that movement speed decreased with age as well as in the left arm…

AdultMalemedicine.medical_specialtyAgingTime FactorsCognitive NeuroscienceMovementExperimental and Cognitive PsychologyIntentionFunctional LateralityDevelopmental psychologyMotor imageryPhysical medicine and rehabilitationTask Performance and AnalysismedicineHumansLearningAgedAnalysis of VarianceMovement (music)Age FactorsMean ageMotor taskNeuropsychology and Physiological PsychologyArmImaginationFemaleAnalysis of varianceYoung groupPsychologyPsychomotor PerformanceCortex; a journal devoted to the study of the nervous system and behavior
researchProduct

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

2021

BackgroundNo adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. MethodsWe conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks fo…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatment[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyB7-H1 AntigenDisease-Free Survival03 medical and health sciences0302 clinical medicineDouble-Blind MethodStomach NeoplasmsInternal medicineMedicine and Health SciencesmedicineCarcinomaHumans030212 general & internal medicineEsophagusImmune Checkpoint InhibitorsNeoadjuvant therapyAgedAged 80 and overChemotherapybusiness.industryCancerChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseNeoadjuvant TherapyIntention to Treat Analysis3. Good healthNivolumabmedicine.anatomical_structureChemotherapy AdjuvantCarcinoma Squamous CellFemaleEsophagogastric JunctionNivolumabbusinessAdjuvantChemoradiotherapyNew England Journal of Medicine
researchProduct

Efficacy and safety of an intraoral electrostimulation device for xerostomia relief: a multicenter, randomized trial.

2011

Objective To evaluate the efficacy and safety of an intraoral electrostimulation device, consisting of stimulating electrodes, an electronic circuit, and a power source, in treating xerostomia. The device delivers electrostimulation through the oral mucosa to the lingual nerve in order to enhance the salivary reflex. Methods The device was tested on a sample of patients with xerostomia due to Sjogren's syndrome and other sicca conditions in a 2-stage prospective, randomized, multicenter trial. Stage I was a double-blind, crossover stage designed to compare the effects of the electrically active device with the sham device, each used for 1 month, and stage II was a 3-month open-label stage d…

AdultMalemedicine.medical_specialtyImmunologySettore MED/50 - Scienze Tecniche Mediche ApplicateElectric Stimulation TherapySeverity of Illness IndexXerostomialaw.inventionRandomized controlled trialQuality of lifestomatognathic systemRheumatologyDouble-Blind MethodlawSettore MED/28 - Malattie OdontostomatologicheMulticenter trialSeverity of illnessotorhinolaryngologic diseasesImmunology and AllergyMedicineHumansPharmacology (medical)Prospective StudiesOral mucosaProspective cohort studyAgedxerostomia; dry mouth; salivary gland hypofunction; saliva; electrical stimulation; electrostimulation; Sjögren’s syndromeIntention-to-treat analysisToxicitybusiness.industryMouth MucosaMiddle AgedDry mouthSurgeryOral cavityIntention to Treat Analysisstomatognathic diseasesmedicine.anatomical_structureSjogren's SyndromeTreatment OutcomeAnesthesiaFemalemedicine.symptombusinessArthritis and rheumatism
researchProduct

Bone Marrow Concentrate and Bovine Bone Mineral for Sinus Floor Augmentation

2011

Purpose: The purpose of this work was to evaluate the potential of substituting autogenous bone (AB) by bone marrow aspirate concentrate (BMAC). Both AB and BMAC were tested in combination with a bovine bone mineral (BBM) for their ability of new bone formation (NBF) in a multicentric, randomized, controlled, clinical and histological noninferiority trial.Materials and Methods: Forty-five severely atrophied maxillary sinus from 26 patients were evaluated in a partial cross-over design. As test arm, 34 sinus of 25 patients were augmented with BBM and BMAC containing mesenchymal stem cells. Eleven control sinus from 11 patients were augmented with a mixture of 70% BBM and 30% AB. Biopsies wer…

AdultMalemedicine.medical_specialtySinus Floor AugmentationOSTEOGENIC DIFFERENTIATIONBone RegenerationMaxillary sinusBiomedical EngineeringSinus Floor AugmentationBioengineeringBiochemistryMAXILLARY SINUSlaw.inventionMESENCHYMAL STEM-CELLSBIO-OSSBiomaterialsRandomized controlled trialTISSUE-ENGINEERED BONEBone MarrowOsteogenesislawmedicineAnimalsHumansSingle-Blind MethodSinus (anatomy)AgedIMPLANT PLACEMENTHYDROXYAPATITE CERAMICSBone TransplantationIntention-to-treat analysisPOROUS HYDROXYAPATITEbusiness.industryIN-VITROMiddle AgedSurgeryAUTOGENOUS BONEImplant placementBovine bonemedicine.anatomical_structureBone SubstitutesCattleFemaleBone marrowbusinessTissue Engineering. Part A
researchProduct

Individual music therapy for depression: randomised controlled trial

2011

BackgroundMusic therapy has previously been found to be effective in the treatment of depression but the studies have been methodologically insufficient and lacking in clarity about the clinical model employed.AimsTo determine the efficacy of music therapy added to standard care compared with standard care only in the treatment of depression among working-age people.MethodParticipants (n= 79) with an ICD–10 diagnosis of depression were randomised to receive individual music therapy plus standard care (20 bi-weekly sessions) or standard care only, and followed up at baseline, at 3 months (after intervention) and at 6 months. Clinical measures included depression, anxiety, general functioning…

AdultMalemedicine.medical_specialtyTime FactorsMusic therapyAdolescentAnxietySeverity of Illness Indexlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Randomized controlled triallawSeverity of illnessmedicineHumansAffective Symptoms030212 general & internal medicinePsychiatryMusic TherapyFinlandDepression (differential diagnoses)ta515Psychiatric Status Rating ScalesDepressive DisorderIntention-to-treat analysisOdds ratioMiddle Agedta3124Intention to Treat Analysis030227 psychiatryPsychiatry and Mental healthOutcome and Process Assessment Health Careta6131Quality of LifePhysical therapyPsychotherapy BriefAnxietyFemalemedicine.symptomPsychologyProgram EvaluationThe British Journal of Psychiatry
researchProduct

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double-Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

2018

Objective: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti–double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. Methods: In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA–SLEDAI] score ≥8) were randomized (2:1) to receive weekl…

AdultMalemedicine.medical_specialtymedicine.drug_classInjections SubcutaneousPopulationImmunologyPlaceboAntibodies Monoclonal HumanizedGastroenterologySystemic Lupus ErythematosusSeverity of Illness Index03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicinemedicineHumansLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineeducationAdverse effectskin and connective tissue diseases030203 arthritis & rheumatologyeducation.field_of_studyLupus erythematosusIntention-to-treat analysisbusiness.industryComplement C3DNAmedicine.diseaseBelimumabRheumatologyIntention to Treat AnalysisTreatment OutcomeAntibodies AntinuclearImmunology and Allergy; Rheumatology; ImmunologyCorticosteroidOriginal ArticleFemalebusinessmedicine.drug
researchProduct